Schematic showing IL-6-induced STAT3-to-PI3K signaling switch in colorectal cancer stem cells, driving ZEB1-dependent PD-L1 expression and immune evasion. A landmark study published in Science ...
Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026. Click for more on RLAY stock.
Severe hyperglycemia has emerged as a common side effect among patients with PIK3CA-mutated breast cancer treated with the PI3K inhibitor alpelisib (Piqray), especially patients treated outside a ...
MEI Pharma Inc. has discontinued the global development of its phosphoinositide 3-kinase (PI3K) delta inhibitor, zandelisib, outside Japan. “In light of FDA’s guidance, we no longer believe clinical ...
Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash ...
Intellikine has option to participate in U.S. commercialization of delta and gamma inhibitors. Infinity Pharmaceuticals is paying Intellikine $13.5 million in initial license fees as part of the firms ...
Bayer AG said it will voluntarily withdraw Aliqopa (copanlisib) from the U.S. market after a confirmatory trial required by the FDA failed to meet the primary endpoint of progression-free survival vs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results